MichaelScottShermanMD

Summary

• Dr. Michael Sherman serves as venture partner at RA Capital Management, a $10 billion multi-stage investment manager, dedicated to evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools.
  
  Prior to joining RA, he served as executive vice president and chief medical officer at Point32Health, formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan, two leading not-for-profit health plans insuring over 2 million members. Prior to the merger, Dr. Sherman served as chief medical officer of Harvard Pilgrim Health Care, nationally recognized for both innovation and quality. He has been widely recognized as a pioneer in bringing advances in transformational therapeutics, precision medicine, and digital therapeutics to Point32Health’s members by launching structured pilots that balance access and affordability and also generate real world evidence.
  
  In 2018, he received Xconomy’s “Contrarian Award” for his contributions, including having signed the nation’s first such payment model for a gene therapy, helping pave the way for developing innovative financing models. Dr. Sherman’s work is also featured in a Harvard Business School case study published in 2021.
  
  Dr. Sherman holds board appointments with several well-respected nonprofit organizations, including the Personalized Medicine Coalition, the Harvard Business School Healthcare Initiative, and NEHI (Network for Excellence in Health Innovation). For a decade, he served as chair of the Board of Managers of the Harvard Pilgrim Health Care Institute, which encompasses the Department of Population Medicine at Harvard Medical School—the nation’s only appointing medical school department based in a health plan.
  
  Before pursuing an M.B.A. at Harvard Business School, Dr. Sherman received his M.D. from Yale and practiced as a cardiac anesthesiologist.